Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MARINUS PHARMACEUTICALS, INC.

(MRNS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/20/2022 01/21/2022 01/24/2022 01/25/2022 01/26/2022 Date
10.56(c) 10.28(c) 10.67(c) 10.13(c) 9.68 Last
88 969 180 126 221 931 94 880 224 394 Volume
-2.22% -2.65% +3.79% -5.06% -4.44% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 17,3 M - -
Net income 2021 -98,8 M - -
Net cash position 2021 81,3 M - -
P/E ratio 2021 -3,60x
Yield 2021 -
Sales 2022 24,1 M - -
Net income 2022 -114 M - -
Net cash position 2022 83,1 M - -
P/E ratio 2022 -3,43x
Yield 2022 -
Capitalization 356 M 356 M -
EV / Sales 2021 15,9x
EV / Sales 2022 11,3x
Nbr of Employees 100
Free-Float 99,8%
More Financials
Company
Marinus Pharmaceuticals Inc is a United States-based biopharmaceutical company. The Company offers development and commercialization of medical drugs for the treatment of serious neurological and psychiatric disorders such as epilepsy, post-traumatic stress, and fragile-x syndrome. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral... 
Sector
Pharmaceuticals
Calendar
02/18 | 10:00amPresentation
More about the company
Ratings of Marinus Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about MARINUS PHARMACEUTICALS, INC.
01/20Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ..
AQ
01/17Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
01/14Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4..
BU
01/13Epilepsy Pipeline, Emerging Therapies, Key Pharma Players, Clinical Trials, Growth Pros..
AQ
01/05Marinus Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference..
BU
2021Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4..
BU
2021SVB Leerink Adjusts Marinus Pharmaceuticals' Price Target to $30 from $32, Keeps Outper..
MT
2021Marinus Pharmaceuticals Announces New Clinical and Research Data to be presented at Ame..
AQ
2021Marinus Pharmaceuticals Shares New Data on Ganaxolone
MT
2021Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at Ame..
BU
2021Marinus Pharmaceuticals, Inc. Announces New Clinical and Research Data to Be Presented ..
CI
2021Marinus Pharmaceuticals Announces Nine Presentations and Virtual Investor Event at Amer..
BU
2021Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
BU
2021MARINUS PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Conditio..
AQ
2021Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financi..
PU
More news
News in other languages on MARINUS PHARMACEUTICALS, INC.
2021Marinus Pharmaceuticals présente de nouvelles données sur le ganaxolone
2021Earnings Flash (MRNS) MARINUS PHARMACEUTICALS annonce un chiffre d'affaires de 10,1 mil..
2021Marinus Pharmaceuticals, Inc. révise ses prévisions de bénéfices pour l'exercice 2021
2021Marinus Pharmaceuticals annonce des résultats positifs de l'essai de phase II d'un médi..
2021Marinus Pharmaceuticals annonce une perte plus importante au deuxième trimestre et revo..
More news
Analyst Recommendations on MARINUS PHARMACEUTICALS, INC.
More recommendations
Chart MARINUS PHARMACEUTICALS, INC.
Duration : Period :
Marinus Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MARINUS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 9,68 $
Average target price 29,89 $
Spread / Average Target 209%
EPS Revisions
Managers and Directors
Scott N. Braunstein President, Chief Executive Officer & Director
Steven E. Pfanstiel Chief Financial Officer & Treasurer
Nicole Vitullo Chairman
Joseph Hulihan Chief Medical Officer
Tim M. Mayleben Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MARINUS PHARMACEUTICALS, INC.-14.73%372
JOHNSON & JOHNSON-2.01%441 302
ROCHE HOLDING AG-8.68%304 745
PFIZER, INC.-11.02%294 900
ABBVIE INC.-1.71%235 287
ELI LILLY AND COMPANY-13.31%217 093